Abstract No guidelines currently exist for the management of Candida auris bloodstream infection in patients with left ventricular assist devices (LVAD). We aim to share our management experience through this retrospective case series outlining 15 episodes of C. auris candidemia identified in 7 patients over 18 months. The initial source of candidemia was central venous catheter (CVC) in five patients, driveline exit site (DLES) infection in one patient, and possible pump infection in one patient. All patients were initially treated with micafungin. Despite susceptibility to micafungin, four patients experienced recurrent C. auris candidemia. All patients died within one year of their first episode of C. auris candidemia. Source control is challenging in patients with LVADs and strict infection prevention measures should be practiced. More studies are needed to evaluate the role of newer antifungal agents, use of combination antifungal regimens, and impact on morbidity in patients with LVADs.